A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Luca Stingeni , Leonardo Bianchi , Elettra Antonelli , Elena Sofia Caroppo , Silvia Mariel Ferrucci , Carlotta Gurioli , Michela Ortoncelli , Gabriella Fabbrocini , Eustachio Nettis , Donatella Schena , Maddalena Napolitano , Massimo Gola , Laura Bonzano , MariaTeresa Rossi , Anna Belloni Fortina , Anna Balato , Ketty Peris , Caterina Foti , Fabrizio Guarneri , Marco Romanelli , Cataldo Patruno , Paola Savoia , Maria Esposito , Filomena Russo , Enzo Errichetti , Tommaso Bianchelli , Luca Bianchi , Giovanni Pellacani , Claudio Feliciani , Annamaria Offidani , Monica Corazza , Giuseppe Micali , Nicola Milanesi , Giovanna Malara , Andrea Chiricozzi , Marta Tramontana , Katharina Hansel Journal of the European Academy of Dermatology and Venereology : JEADV(2023)
Key words
atopic dermatitis, dupilumab, adolescents
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper